Source link : https://www.newshealth.biz/health-news/novel-agent-first-to-slow-disability-in-nrspms/
COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The Phase 3 HERCULES trial showed tolebrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, delayed the time to onset of 6-month confirmed disability progression by 31% compared with placebo. In addition, […]
Author : News Health
Publish date : 2024-09-20 20:13:23
Copyright for syndicated content belongs to the linked Source.
Categories